Updating results

3465 results

Sort: Relevance | Date

Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published January 2013

Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

Evidence summary Published March 2016

Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...

Evidence summary Published June 2014

Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

Evidence summary Published December 2015

Erectile dysfunction: Alprostadil cream (ESNM50)

Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published December 2014

Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Skin involvement in systemic sclerosis: rituximab (ES7)

Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

Evidence summary Published March 2017

Asthma: tiotropium (Spiriva Respimat) (ESNM55)

Summary of the evidence on tiotropium (Spiriva Respimat) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Erectile dysfunction: avanafil (ESNM45)

Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published August 2014

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

Evidence summary Published February 2017

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015

Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

Summary of the evidence on tiotropium/olodaterol (Spiolto Respimat) for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published May 2016

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Type 2 diabetes: dulaglutide (ESNM59)

Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published June 2015

Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

Summary of the evidence on beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) for treating asthma in adults..

Evidence summary Published January 2015

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..

Evidence summary Published January 2015

Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making

Evidence summary Published January 2015

Schizophrenia: lurasidone (ESNM48)

Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

Evidence summary Published September 2014

Type 2 diabetes: insulin degludec (ESNM25)

Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Parkinson's disease with motor fluctuations: safinamide (ES6)

Summary of the evidence on safinamide for treating Parkinson’s disease with motor fluctuations to inform local NHS planning and decision-making

Evidence summary Published February 2017

Refractory extrapulmonary sarcoidosis: infliximab (ES4)

Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published January 2017

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2014

Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

Summary of the evidence on opicapone for reducing end-of-dose motor fluctuations in Parkinson’s disease to inform local NHS planning and decision-making

Evidence summary Published March 2017

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

Summary of the evidence on the indacaterol/glycopyrronium (Ultibro Breezhaler) for relieving the symptoms of chronic obstructive pulmonary disease (COPD)..

Evidence summary Published February 2014 Last updated March 2014

Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

Evidence summary Published September 2014

Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published September 2014

PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)

Advice on the use of PleuraFlow Active Clearance Technology (ACT) for maintaining chest tube patency to aid local decision-making

Medtech innovation briefing Published October 2017

Health app: ChatHealth communication platform in school nursing services (MIB130)

Advice on the use of the ChatHealth app for anonymous and confidential communication between patients and healthcare professionals in school nursing services

Medtech innovation briefing Published November 2017

Aptiva for painful diabetic neuropathy (MIB119)

Advice on the use of Aptiva for painful diabetic neuropathy to aid local decision-making

Medtech innovation briefing Published September 2017

Next-generation sequencing panel for solid tumour cancers in children (MIB133)

Advice on the use of the next-generation sequencing (NGS) panel for solid tumour cancers in children to aid local decision-making

Medtech innovation briefing Published January 2018

Farco-fill Protect for indwelling urinary catheterisation (MIB121)

Advice on the use of Farco-fill Protect for inflating Foley catheter balloons for indwelling (in-situ) urinary catheterisation to aid local decision-making

Medtech innovation briefing Published September 2017

Thora-3Di for assessing asthma in children (MIB122)

Advice on the use of Thora-3Di for assessing asthma in children (paediatric) to aid local decision-making

Medtech innovation briefing Published October 2017

Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)

Advice on the use of Memokath-028, 044 and 045 stents for urethral obstruction and bladder neck or outlet obstructions in men to aid local decision-making

Medtech innovation briefing Published October 2017

Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

Advice on the use of Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema to aid local decision-making

Medtech innovation briefing Published April 2018

Omega-3 fatty acid supplements (KTT4)

KTT4 KTT4

Key therapeutic topic Published January 2015

Three-day courses of antibiotics for uncomplicated urinary tract infection (KTT10)

KTT10 KTT10

Key therapeutic topic Published January 2015 Last updated February 2016

Airglove air warming system for venous access (MIB151)

Advice on the use of Airglove air warming system for venous access to aid local decision-making

Medtech innovation briefing Published July 2018

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS

Evidence summary Published June 2018

ORA G3 to measure corneal hysteresis (MIB150)

Advice on the use of ORA (Ocular Response Analyzer) G3 for measuring corneal hysteresis during diagnosis and management of glaucoma to aid local decision-making

Medtech innovation briefing Published June 2018

VIDAvision for lung volume analysis in emphysema (MIB148)

Advice on the use of VIDAvision for lung volume analysis in advanced emphysema to aid local decision-making

Medtech innovation briefing Published June 2018

Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

Evidence summary Published November 2016

Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

Evidence summary Published March 2017

Hyperhidrosis: oxybutynin (ES10)

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017